Education
About Us
Working with TipRanks
Follow Us
LifeVantage Corp (LFVN)
NASDAQ:LFVN
Top Page
LifeVantage
(NASDAQ:LFVN)
Select Model
Select Model
Rating:67Neutral
Price Target:
$13.00
▲(30.13% Upside)
LifeVantage's overall stock score reflects a solid financial performance and positive earnings call sentiment, driven by strategic acquisitions and partnerships. However, technical analysis indicates potential bearish momentum, and the valuation is moderate. The significant decline in free cash flow growth is a concern that weighs on the score.
LifeVantage (LFVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$130.46M
Dividend Yield1.65%
Average Volume (3M)161.46K
Price to Earnings (P/E)14.0
Beta (1Y)-0.34
Revenue Growth14.17%
EPS Growth235.39%
CountryUS
Employees222
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)0.17
Shares Outstanding12,691,009
10 Day Avg. Volume200,746
30 Day Avg. Volume161,462
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda10.45
Forecast
1Y Price Target
$13.00Price Target Upside30.13% Upside
Rating ConsensusHold
Number of Analyst Covering0
LifeVantage Business Overview & Revenue Model
Company DescriptionLifeVantage Corporation (LFVN) is a biotechnology company that focuses on developing and marketing dietary supplements and wellness products. The company operates primarily in the health and wellness sector, with a strong emphasis on nutritional supplements that utilize patented technologies to promote cellular health and longevity. Its core product lines include Protandim, a supplement designed to reduce oxidative stress, and other products that support overall health and wellness, targeting both individual consumers and independent distributors.
How the Company Makes MoneyLifeVantage generates revenue primarily through the sale of its nutritional supplements and wellness products. The company employs a direct-selling business model, where products are sold through a network of independent distributors who earn commissions on their sales and the sales of their recruited team members. This multi-level marketing structure not only drives sales but also incentivizes distributors to expand their network. Significant revenue streams include product sales to consumers, distributor commissions, and bonuses, which are tied to sales volume and recruitment. Partnerships with health and wellness professionals and affiliations with wellness-related organizations also bolster the company's brand presence and sales efforts, contributing to its overall earnings.
LifeVantage Earnings Call Summary
Earnings Call Date:Sep 04, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant growth in revenue and strategic initiatives, such as the acquisition of LoveBiome and the partnership with Shopify. However, there was some concern over the softness in U.S. revenue and the decline in operating income. The overall sentiment is cautiously optimistic, with more highlights than lowlights.Q4-2025 Updates
Positive Updates
Revenue Growth and Margin Expansion
Revenues increased approximately 13% year-over-year to $55.1 million, with a 40 basis points expansion in gross margin. Adjusted EBITDA was $4.8 million, flat compared to last year's fourth quarter.
International Business Returns to Growth
For the first time in 12 quarters, the international business showed growth, with revenues in Asia Pacific and Europe regions increasing by 8%.
Strategic Acquisition of LoveBiome
LifeVantage announced the acquisition of LoveBiome, focusing on the gut health sector, which is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, a CAGR of 8.4%.
Partnership with Shopify
LifeVantage entered an agreement with Shopify to modernize its technology and marketing stack, aiming for significant growth potential.
Positive Cash Flow and Shareholder Returns
Finished the fiscal year with $20.2 million in cash and no debt. Repurchased approximately 160,000 shares and announced a quarterly cash dividend.
Negative Updates
U.S. Revenue Softness
The fourth-quarter revenue of $55.1 million was at the lower end of expectations, attributed to softness in the U.S. market.
Operating Income Decline
Adjusted non-GAAP operating income decreased to $2.5 million from $3.2 million in the prior year period, primarily due to higher variable employee compensation-related expenses and increased marketing investments.
Seasonality Impact on MindBody Product Line
Experienced seasonality impact on the MindBody GLP-1 system in the U.S., contributing to the lower-than-expected fourth-quarter revenue.
Company Guidance
During the call, LifeVantage Corporation provided guidance for fiscal 2026, projecting full-year revenue in the range of $225 million to $240 million. The company expects adjusted non-GAAP EBITDA to be between $23 million and $26 million, with adjusted non-GAAP earnings per share anticipated to fall between $1 and $1.15. Additionally, LifeVantage highlighted the expected revenue contribution from their recent acquisition of LoveBiome, which is projected to bolster the company's performance in the second half of fiscal 2026. LifeVantage emphasized the strategic importance of the LoveBiome acquisition, which aligns with their focus on the growing global gut health supplement market, projected to expand from $14.4 billion in 2025 to $32.4 billion by 2035.LifeVantage Financial Statement Overview
Summary
LifeVantage demonstrates solid financial performance with consistent revenue growth and strong profitability margins. The balance sheet reflects a stable leverage position and improved return on equity. However, the significant decline in free cash flow growth poses a risk that needs to be addressed.Income Statement
LifeVantage shows a consistent revenue growth trend with a recent increase of 2.78% in 2025, recovering from previous declines. The gross profit margin remains strong at over 80%, indicating efficient cost management. However, the net profit margin is relatively low at 4.29%, suggesting room for improvement in profitability. The EBIT and EBITDA margins have improved, reflecting better operational efficiency.75
Positive
Balance Sheet
The company's debt-to-equity ratio has decreased to 0.34, indicating a healthier leverage position compared to previous years. Return on equity has improved significantly to 28.30%, showcasing effective use of equity to generate profits. However, the equity ratio is not explicitly provided, but the overall balance sheet indicates a stable financial position with manageable debt levels.70
Positive
Cash Flow
Free cash flow has decreased significantly, with a growth rate of -81.8%, which is a concern. However, the operating cash flow to net income ratio is 0.44, indicating that the company generates sufficient cash from operations relative to its net income. The free cash flow to net income ratio is strong at 1.0, suggesting that the company is able to convert its earnings into cash effectively.65
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 228.53M | 228.53M | 200.16M | 213.40M | 206.36M | 220.18M |
| Gross Profit | 183.67M | 183.67M | 158.72M | 170.01M | 168.26M | 181.99M |
| EBITDA | 15.61M | 15.36M | 7.93M | 4.26M | 9.75M | 23.07M |
| Net Income | 9.80M | 9.80M | 2.94M | 2.54M | 3.12M | 12.89M |
Balance Sheet | ||||||
| Total Assets | 71.96M | 71.96M | 60.30M | 66.12M | 70.71M | 78.73M |
| Cash, Cash Equivalents and Short-Term Investments | 20.20M | 20.20M | 16.89M | 21.61M | 20.19M | 23.17M |
| Total Debt | 11.68M | 11.68M | 13.61M | 13.09M | 15.76M | 18.18M |
| Total Liabilities | 37.32M | 37.32M | 34.31M | 31.47M | 39.19M | 41.92M |
| Stockholders Equity | 34.64M | 34.64M | 25.99M | 34.65M | 31.52M | 36.81M |
Cash Flow | ||||||
| Free Cash Flow | 10.51M | 10.51M | 9.95M | 3.76M | 6.43M | 12.53M |
| Operating Cash Flow | 11.88M | 11.88M | 12.20M | 6.83M | 7.96M | 16.27M |
| Investing Cash Flow | -1.37M | -1.37M | -2.25M | -3.06M | -1.53M | -3.73M |
| Financing Cash Flow | -7.60M | -7.60M | -14.42M | -2.36M | -8.95M | -11.45M |
LifeVantage Technical Analysis
Negative
9.99
Price Trends
12.53
Negative
12.57
Negative
14.82
Negative
Market Momentum
-0.71
Positive
30.03
Neutral
11.58
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 9.99 is below the 20-day moving average (MA) of 11.55, below the 50-day MA of 12.53, and below the 200-day MA of 14.82, indicating a bearish trend. The MACD of -0.71 indicates Positive momentum. The RSI at 30.03 is Neutral, neither overbought nor oversold. The STOCH value of 11.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.
LifeVantage Risk Analysis
LifeVantage disclosed 50 risk factors in its most recent earnings report. LifeVantage reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LifeVantage Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | 289.58M | 21.78 | 8.95% | ― | 4.33% | -6.33% | |
72 Outperform | 727.70M | 16.76 | 6.74% | ― | 7.30% | -13.73% | |
67 Neutral | $130.46M | 14.00 | 32.34% | 1.65% | 14.17% | 235.39% | |
64 Neutral | 528.24M | 15.69 | 7.90% | ― | 2.75% | -37.25% | |
63 Neutral | 925.89M | 2.75 | -49.21% | ― | -2.25% | 288.79% | |
47 Neutral | 148.98M | -0.26 | -111.75% | ― | -10.17% | -609.02% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
Performance Comparison
LFVN
LifeVantage
9.99
-2.83
-22.07%
HLF
Herbalife
8.75
1.34
18.08%
NATR
Nature's Sunshine Products
16.24
2.20
15.67%
SENEA
Seneca Foods
104.50
41.51
65.90%
HAIN
Hain Celestial
1.56
-7.01
-81.80%
USNA
USANA Health
28.29
-9.63
-25.40%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.